SAR 422459

Drug Profile

SAR 422459

Alternative Names: ATP-binding transporter gene therapy; SAR422459; Stargardt disease gene therapy - Oxford BioMedica/Sanofi; StarGen

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oxford BioMedica
  • Developer Oxford BioMedica; Sanofi
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eye disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Stargardt disease

Most Recent Events

  • 16 Sep 2015 Phase-I/II development is ongoing for Stargardt disease 1 in USA and France (NCT01367444, NCT01736592)
  • 17 Oct 2013 Oxford BioMedica reaches an agreement with the US FDA and ANSM to resume recruitment into the phase I/IIa trial for Stargardt disease 1 in USA and France
  • 03 Jun 2013 Oxford BioMedica suspends enrolment in its phase I/II trial for Stargardt disease 1 in USA (NCT01367444)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top